JD Brenton, SA Aparicio, C Caldas
Journal name: 
Breast Cancer Res
Citation info: 
Breast cancers differ in response to treatment and may have a divergent clinical course despite having a similar histopathological appearance. New technology using DNA microarrays provides a systematic method to identify key markers for prognosis and treatment response by profiling thousands of genes expressed in a single cancer. Microarray profiling of 38 invasive breast cancers now confirms striking molecular differences between ductal carcinoma specimens and suggests a new classification for oestrogen-receptor negative breast cancer. Future approaches will need to include methods for high-throughput clinical validation and the ability to analyze microscopic samples.
Research group: 
Caldas Group, Brenton Group
E-pub date: 
01 Aug 2001
Users with this publication listed: 
Carlos Caldas
James Brenton